NCT06607003View on ClinicalTrials.gov

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2026

Conditions
Malaria
Interventions
BIOLOGICAL

P. vivax challenge agent derived from PvHMB-CCE001

P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.

BIOLOGICAL

P. vivax challenge agent derived from PvHMB-CCE002

P. vivax challenge agent derived from PvHMB-CCE002 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH